ORBIMED ADVISORS LLC
Q2 2023 13F-HR Holdings
Net value change ($000)
+424,864
(8.3%)
New positions
16
Sold out positions
12
Turnover %
11.7%
Sector allocation + QoQ delta (equities-only)
Holdings aggregated across other managers listed in the original SEC filing. View detailed breakdown
Snapshot: Change Analysis
Compared to Q1 2023
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| ACELYRIN, Inc. | 111,320 | NEW |
| BAX | 90,410 | 142.7% |
| UTHR | 88,719 | NEW |
| MDGL | 74,282 | NEW |
| ISRG | 53,655 | 33.8% |
| IRON | 52,678 | 109.5% |
| CI | 45,177 | NEW |
| VectivBio Holding AG | 43,780 | 99.8% |
| R1 RCM Inc. /DE | 37,236 | 141.9% |
| ZBH | 35,672 | NEW |
Top Reduces (Value $000, Stocks/ETFs)
| BMY | -67,027 | -41.3% |
| CHINOOK THERAPEUTICS, INC. | -46,978 | -100.0% |
| SRPT | -44,341 | -37.2% |
| BELLUS Health Inc. | -36,756 | -100.0% |
| PGNY | -33,338 | -100.0% |
| AMLX | -23,868 | -100.0% |
| TERN | -23,544 | -26.1% |
| ACET | -22,673 | -52.9% |
| SYK | -22,138 | -21.1% |
| XBI | -20,882 | -100.0% |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
40,384
(0.7% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|